Seeliger: Hemofarm set triple record in 2019

The Serbian pharmaceuticals company Hemofarm will end this year with a total output of 5.7 bln tablets and other forms of medicines, or around 280 mln medicine packages, says Hemofarm CEO Ronald Seeliger.

06 Decembar 2019 17:16

BELGRADE - The Serbian pharmaceuticals company Hemofarm will end this year with a total output of 5.7 bln tablets and other forms of medicines, or around 280 mln medicine packages, says Hemofarm CEO Ronald Seeliger.

Speaking at the company's New Year gathering late Thursday, he said 2019 was one of the most successful years in the recent history of Hemofarm, which he said had set a triple record - in terms of production output, product portfolio as well as sales.

He said the Hemofarm product portfolio would at the end of the year be comprised of 3,150 different products.

Noting that the company would next year celebrate its 60th anniversary, he said Hemofarm operations were not only about results but also about care for the health of people in Serbia and around the world as the company's medicines were marketed on as many as three continents.

Hemofarm is a part of the global pharmaceuticals giant Stada Group.

Photo: Tanjug/A. Vukelic

top of page